Bardin Hill Management Partners LP Sells 131,432 Shares of Enhabit, Inc. (NYSE:EHAB)

Bardin Hill Management Partners LP reduced its stake in shares of Enhabit, Inc. (NYSE:EHAB - Free Report) by 88.6% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 16,966 shares of the company's stock after selling 131,432 shares during the quarter. Enhabit accounts for approximately 0.1% of Bardin Hill Management Partners LP's holdings, making the stock its 24th largest holding. Bardin Hill Management Partners LP's holdings in Enhabit were worth $151,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Empowered Funds LLC increased its holdings in Enhabit by 87.7% during the 1st quarter. Empowered Funds LLC now owns 147,594 shares of the company's stock worth $1,719,000 after purchasing an additional 68,966 shares during the last quarter. DekaBank Deutsche Girozentrale grew its stake in shares of Enhabit by 39.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 340,412 shares of the company's stock worth $3,861,000 after purchasing an additional 95,488 shares in the last quarter. Orchard Capital Management LLC grew its stake in shares of Enhabit by 5.6% in the fourth quarter. Orchard Capital Management LLC now owns 600,350 shares of the company's stock worth $6,214,000 after purchasing an additional 31,929 shares in the last quarter. WINTON GROUP Ltd bought a new position in Enhabit during the second quarter valued at about $955,000. Finally, 8 Knots Management LLC bought a new position in Enhabit during the fourth quarter valued at about $1,968,000.

Wall Street Analysts Forecast Growth

Separately, Bank of America decreased their target price on Enhabit from $9.00 to $8.00 and set an "underperform" rating for the company in a research note on Thursday, June 27th. One research analyst has rated the stock with a sell rating and six have issued a hold rating to the stock. Based on data from MarketBeat, Enhabit currently has an average rating of "Hold" and an average target price of $9.35.

Enhabit Stock Down 0.4 %

Enhabit stock traded down $0.03 during mid-day trading on Wednesday, hitting $7.51. The company's stock had a trading volume of 409,911 shares, compared to its average volume of 616,375. The firm's 50 day moving average is $8.52 and its 200 day moving average is $9.26. The company has a market cap of $376.67 million, a PE ratio of -4.51 and a beta of 1.82. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.48 and a quick ratio of 1.48. Enhabit, Inc. has a 52-week low of $7.12 and a 52-week high of $11.74.

Enhabit (NYSE:EHAB - Get Free Report) last issued its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.05 by $0.02. Enhabit had a positive return on equity of 1.61% and a negative net margin of 0.84%. The company had revenue of $260.60 million for the quarter, compared to analyst estimates of $265.99 million. During the same period in the prior year, the firm posted $0.04 EPS. On average, analysts anticipate that Enhabit, Inc. will post 0.26 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Jeffrey Bolton acquired 5,000 shares of the stock in a transaction dated Thursday, August 22nd. The shares were acquired at an average price of $8.01 per share, with a total value of $40,050.00. Following the acquisition, the director now owns 78,877 shares in the company, valued at approximately $631,804.77. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 1.90% of the company's stock.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.